- MiNK Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient with Severe ARDS at ATS Annual Meeting
- MiNK Reports First Quarter 2024 Results
- MiNK Therapeutics Announces $5.8 Million Private Placement and Appointment of Board Observer
- MiNK to Provide Corporate Update and First Quarter 2024 Financial Report
- MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR
- MiNK Reports Fourth Quarter and Year-End 2023 Results
- MiNK to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report
- MiNK Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024
- First Refractory Gastric Cancer Patient Dosed in Phase 2 Trial with Novel Combination of MiNK’s Allogeneic INKT Cell Therapy and Agenus’ Botensilimab and Balstilimab
- MiNK Therapeutics' AgenT-797 Shows Promising Results in the Treatment of Severe Acute Respiratory Distress, Published in Nature Communications
More ▼
Key statistics
On Wednesday, Mink Therapeutics Inc (INKT:NAQ) closed at 1.00, 33.33% above the 52 week low of 0.75 set on Jan 16, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.01 |
---|---|
High | 1.02 |
Low | 0.9409 |
Bid | 0.97 |
Offer | 1.01 |
Previous close | 0.99 |
Average volume | 622.40k |
---|---|
Shares outstanding | 39.37m |
Free float | 14.63m |
P/E (TTM) | -- |
Market cap | 38.97m USD |
EPS (TTM) | -0.5964 USD |
Data delayed at least 15 minutes, as of May 22 2024 21:00 BST.
More ▼